Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Thursday, Elicio Therapeutics Inc (NASDAQ:ELTX) released new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P.
2024年5月24日，Elicio Therapeutics公司（納斯達克股票代碼：ELTX）發佈了其非個性化調查治療癌症疫苗候選ELI-002 7P進行的AMPLIFY-7P 1a期研究的最新初步數據。
The preliminary data showed patients receiving ELI-002 7P at the Phase 2 dose of 4.9mg AMP-peptide were yet to reach the median disease-free survival (DFS) endpoint as of the May 24, 2024 data cutoff date.
初步數據顯示，截至2024年5月24日截止日期，接受4.9毫克AMP-肽劑量的ELI-002 7P的患者尚未達到中位無疾病生存（DFS）終點。
The AMPLIFY-7P study is evaluating the 7-peptide formulation ELI-002 7P in patients with mKRAS-driven solid tumors following standard locoregional treatment.
AMPLIFY-7P研究評估標準治療後mKRAS驅動的實體瘤患者中的7肽配方ELI-002 7P。
Data were based on May 24, 2024, data cutoff date of 14 patients with minimal residual disease who enrolled in the Phase 1 cohort of the AMPLIFY-7P study, with a median follow-up for the DFS endpoint of 29.1 weeks:
數據基於AMPLIFY-7P研究1期隊列中14例最小殘留病人的2024年5月24日數據截止日期，DFS終點的中位隨訪時間爲29.1周。
The median DFS has not yet been reached (n=14).
中位DFS尚未達到（n = 14）。
The median disease-free survival (mDFS) has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-peptide dose (n=6).
接受4.9毫克AMP-肽劑量（n=8）的患者與接受1.4毫克AMP-肽劑量（n=6）的患者相比，中位無病生存期（mDFS）尚未達到。
Patients achieving a reduction in their tumor biomarker levels had no progression events, compared to an mDFS of 11.0 weeks for patients whose tumor biomarker did not respond to ELI-002 7P.
癌症生物標誌物水平降低的患者沒有進展事件，而那些病竈生物標誌物沒有對ELI-002 7P作出反應的患者的mDFS爲11.0周。
Patients with an above-median T-cell response to ELI-002 have had no progression events.
具有高於中位數的T細胞反應的患者的進展情況良好。
The company expects to share additional clinical data updates from the AMPLIFY Phase 1 trials later in 2024 and the randomized Phase 2 interim analysis in the first quarter of 2025.
該公司預計將在2024年晚些時候分享AMPlIFY 1期試驗的額外臨床數據更新，並在2025年第一季度分享隨機化2期中期分析的數據。
ELI-002 2P (2-peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors following surgery and chemotherapy.
ELI-002 2P（2肽劑型）目前正在一項進行中的1期（AMPLIFY-201）試驗中研究高復發風險mKRAS驅動的實體瘤患者，這些患者曾接受手術和化療。
ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer.
ELI-002 7P（7肽配方）目前正在一項1/2期（AMPLIFY-7P）試驗中研究mKRAS驅動的胰腺癌患者。
Concurrently, Elicio Therapeutics priced its approximately $11.5 million public offering of 500k shares and accompanying warrants to purchase 500k shares at a combined price of $5.00.
與此同時，Elicio Therapeutics定價其約1150萬美元的公開發行500,000股股票和可購買500,000股股票的認股權證，總價爲5.00美元。
Price Action: ELTX shares are down 36.9% at $4.345 at last check Friday.
ELTX股票價格上漲，最後一次查詢爲4.345美元，下跌了36.9％。
Image by PDPics from Pixabay
來自Pixabay的PDPics圖片
譯文內容由第三人軟體翻譯。